Drug Search Results
More Filters [+]

ATN-161

Alternative Names: atn-161, atn161, atn 161
Latest Update: 2024-05-01
Latest Update Note: PubMed Publication

Product Description

a five Ðamino-acid peptide derived from the synergy region of fibronectin. ATN-161 is a noncompetitive inhibitor of the fibronectin PHSRN sequence, in which a cysteine residue has been substituted for arginine along with peptide acetylation and amidation in order to yield a product with acceptable pharmaceutical properties (Ac-PHSCN-NH2). Unlike other integrin antagonists ATN-161 does not block integrin-dependent adhesion, but may inhibit integrin-dependent signalling as part of its mechanism of action (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361324/)

Mechanisms of Action: SOD Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Attenuon
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ATN-161

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Brain Stem Cancer|Glioma|Renal Cell Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

06-C-0170

P2

Completed

Brain Stem Cancer|Glioma

2007-01-01

ATN-161-005

P2

Terminated

Renal Cell Carcinoma

None

Recent News Events